絞り込み

16592

広告

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

著者 Jabbour E , Short NJ , Jorgensen JL , Yilmaz M , Ravandi F , Wang SA , Thomas DA , Khoury J , Champlin RE , Khouri I , Kebriaei P , O'Brien SM , Garcia-Manero G , Cortes JE , Sasaki K , Dinardo CD , Kadia TM , Jain N , Konopleva M , Garris R , Kantarjian
Cancer.2016 Sep 7 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (10view , 0users)

Full Text Sources

Medical

Minimal residual disease (MRD) assessment predicts survival for patients with newly diagnosed acute lymphoblastic leukemia (ALL). Its significance in relapsed/refractory ALL is less clear.
PMID: 27602508 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード